As part of method validation, we also demonstrated the ability to measure baseline Top1 levels in 18-gauge needle tumor biopsies collected from patients in clinical trials at the NCI following standard operating procedures established for the clinical poly(ADP-ribose) immunoassay [34]. Here, TOP1 is linked to neoplasm.